In a study, where CKD progression in mice after 5/6 nephrectomy (5/6Nx) plus continuous angiotensin II (AngII) infusion was evaluated, CD36 KO or 5A peptide therapy prevented a decline in kidney function, while 5A treatment did not improve renal function in CD36 KO mice, indicating that CD36 is the major target of action [65]. Here, CD36 is linked to chronic kidney disease.